NCT05140564

Brief Summary

There is currently no effective intervention for type 1 diabetes and eating disorders. The main objective of STEADY Stage 2 is to test the feasibility of the newly developed STEADY intervention. STEADY was co-designed by using Experience Based Co-Design methodology and other qualitative methods (focus groups, interviews). These findings informed the development of a T1DM cognitive behaviour therapy (CBT) manual. The intervention will now be tested in a feasibility Randomised Controlled Trial (RCT) in adults with type 1 diabetes and eating disorders and compared with usual clinical care. If STEADY is feasible, this may provide an effective intervention for this population. This study will take place at King's College London. Participants will remain in the study for 6 months, with a 12-month extended observation period. The study is expected to end in February 2023.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2021

Completed
22 days until next milestone

First Posted

Study publicly available on registry

December 1, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

January 18, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 29, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 29, 2024

Completed
Last Updated

March 5, 2024

Status Verified

March 1, 2024

Enrollment Period

2.1 years

First QC Date

November 9, 2021

Last Update Submit

March 4, 2024

Conditions

Keywords

Type 1 diabetesEating disorderDiabulimiaEDNOS

Outcome Measures

Primary Outcomes (1)

  • HbA1c

    HbA1c measured in mmol/mol

    6 months

Study Arms (2)

STEADY intervention group

EXPERIMENTAL
Behavioral: STEADY intervention

Treatment as usual group (control)

NO INTERVENTION

Interventions

STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.

STEADY intervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (≥18 years);
  • Diagnosis of type 1 diabetes mellitus for at least 6 months;
  • Current disordered eating: defined as fear of insulin as weight gaining, avoidance/ restriction of insulin to control weight, food restriction, binge eating, any additional disordered eating behaviour as described by the 5th revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), or 11th Revision of the International Classification of Diseases (ICD-11); AND/OR score of 15 on EDE-QS, AND/OR a score of 20 on the DEPS-R.
  • Prepared to take part in a cognitive-behavioural therapy approach behaviour change strategy plus diabetes education intervention (with up to 12 sessions) with a varying proportion of face-to-face and virtual delivery mode;
  • Prepared to take part in the control group - treatment as usual (TAU)
  • Prepared to attend physical and mental health check-up at baseline and at the end of the intervention (control arm and intervention arm) face-to-face;
  • Currently under the care of a diabetes specialist team (as this study does not replace usual diabetes care);
  • Confirms availability to attend all sessions as part of the intervention (with the option of rescheduling sessions when necessary. Therapy sessions may be in person or via videoconference);
  • Investigator has confidence that the participant is able to fulfill all of the trial protocol requirements;
  • Participant has capacity to consent to the study. This is assessed by ability to explain information about their involvement in the study.

You may not qualify if:

  • HbA1c \>15%/ 140.4 mmol/mol;
  • More than 2 admissions for DKA in the past 12 months;
  • More than 2 SH episodes (defined as needing 3rd party assistance) in the past 12 months due to insulin omission (not if triggered by infection or canula failure);
  • Severe mental illness, including severe depression with suicidal ideation, psychosis, emotionally unstable personality disorder requiring more intensive psychiatric treatment, substance problem use and dependence. (Potential participants with more severe mental illness are unlikely to benefit from a CBT based approach, therefore will be excluded to not delay their treatment. Investigators will use their clinical judgement, in agreement with the trial team. Mental health assessment by a psychiatrist is part of the baseline visit.);
  • Body mass index below 15kg/m2 or above 40kg/m2;
  • Significant cognitive impairment, e.g. dementia, learning disability;
  • Unable to speak/hear/understand/read/write in English;
  • Unable to give written informed consent;
  • Pregnant or planning pregnancy;
  • Advanced diabetes complications (end stage renal failure, registered blind, limb amputation);
  • Uncontrollable electrolyte disturbance, low blood pressure (\<100/60mmHg), ECG abnormalities related to malnutrition (QTc-prolongation) or other physical conditions requiring inpatient treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King's College Hospital

London, United Kingdom

Location

Related Publications (1)

  • Stadler M, Zaremba N, Harrison A, Brown J, Pillay D, Allan J, Tan R, Ayis S, Konstantara E, Treasure J, Hopkins D, Ismail K. Safety of a co-designed cognitive behavioural therapy intervention for people with type 1 diabetes and eating disorders (STEADY): a feasibility randomised controlled trial. Lancet Reg Health Eur. 2025 Jan 20;50:101205. doi: 10.1016/j.lanepe.2024.101205. eCollection 2025 Mar.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Feeding and Eating DisordersDiabulimia

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesSigns and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 9, 2021

First Posted

December 1, 2021

Study Start

January 18, 2022

Primary Completion

February 29, 2024

Study Completion

February 29, 2024

Last Updated

March 5, 2024

Record last verified: 2024-03

Locations